Insulet Corporation · NASDAQ:PODD
Insulet — Q3 2024 Earnings Presentation
14 slides from Insulet's earnings presentation, Nov 7, 2024
Slide 1: Q3'24 Earnings
Mattie Podder since 2010 Q3'24 Earnings November 7, 2024
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains forward-looking statements regarding, among other things, future operating and financial performance, product success and efficacy, the outcome of studies and trials and the approval of products by regulatory bodies. These forward-looking statemen
Slide 3: Non-GAAP Financial Measures
Non-GAAP Financial Measures The Company uses the following non-GAAP financial measures: • Constant currency revenue growth, which represents the change in revenue between current and prior year periods using the exchange rate in effect during the applicable prior year period. Insulet presents consta
Slide 4: Insulet Abbreviations and Acronyms
Insulet Abbreviations and Acronyms AI Artificial Intelligence G6 Dexcom G6 Sensor AID Automated Insulin Delivery G7 Dexcom G7 Sensor bps Basis Points MDI Multiple Daily Injections CGM Continuous Glucose Monitoring NCS New Customer Starts FDA Food and Drug Administration T1D Type 1 Diabetes FMR Full
Slide 5: Q3'24 Financial Highlights
Q3'24 Financial Highlights1 Total Revenue Omnipod Revenue Other Financial by Geography Highlights U.S. Omnipod $395.6M Gross Margin an increase of 23.4% Total Company Total Omnipod 69.3% $543.9M $533.6M up 150 bps an increase of 25.7%, an increase of or 25.4% 26.4%, or 26.1% in constant currency in
Slide 6: Recent Strategic Highlights
Recent Strategic Highlights U.S. International Clinical & Other Received FDA clearance for Omnipod 5 • Omnipod named the Number One Published results in Diabetes Care for T2D in the U.S.1 making Omnipod 5 insulin pump for new pump users in demonstrating improved glycemic the first and only AID syste
Slide 7: Q3'24 Revenue & Margin Performance
Q3'24 Revenue & Margin Performance $s in Millions Total Revenue1 Total Omnipod1 Gross Profit & Margin (adjusted) 2 U.S. Omnipod1 International Omnipod1 Operating Income & Margin (adjusted) 2 1. Growth rates are on a YoY basis and are in constant currency. See description of non-GAAP financial measur
Slide 8: Key Commercial Metrics
Over 85% Majority of U.S. NCS were MDI of international NCS were Q3'24 Omnipod 5 Key Commercial Over 25% Nearly 100% Metrics of U.S. NCS were type 2 of U.S. volume through pharmacy 8 Note: Some commercial metrics are directional estimates derived from various internal and external data sources.
Slide 9: Omnipod 5 Commercial Execution
Omnipod 5 Commercial Execution U.S. International 2022 2023 2024 FMR FMR FMR FMR FMR FMR FMR FMR FMR U.K. Germany U.K. Netherlands France T2D iOS Omnipod 5 integrated with the following Pod configurations: G6 G6 G6 FSL2 G6 G6 G7 G6 G6 FSL2 Upcoming Commercial Launches Innovation Pipeline Omnipod 5 w
Slide 10: 2024 Guidance Highlights
2024 Guidance Highlights1 Revenue Guidance2 Margin Guidance Assumptions & Drivers Q4'24 FY 2024 FY 2024 FY 2024 Operating Margin Raise Continued strong Omnipod 5 Revenue Revenue Raise Gross Margin adoption globally 12% to 15% 20% to 21% ~69% ~14.5% U.S. & Int'l NCS growth YoY and sequentially in Q4
Slide 11: Appendix
Appendix Insulet
Slide 12: Historical Financial Performance
Historical Financial Performance $s in Millions Total Revenue1 Total Omnipod1 Gross Profit & Margin (adjusted) 2 2 U.S. Omnipod1 International Omnipod1 Operating Income & Margin (adjusted) 2 2 2 1. Growth rates are on a YoY basis and are in constant currency. See description of non-GAAP financial me
Slide 13: Non-GAAP Reconciliation — Revenue Guidance
Non-GAAP Reconciliation — Revenue Guidance Year Ending December 31, 2024 Revenue Growth GAAP Currency Impact Constant Currency U.S. Omnipod 19% to 21% —% 19% to 21% International Omnipod 26% to 28% 1% 25% to 27% Total Omnipod 21% to 22% —% 21% to 22% Drug Delivery (10)% to (5)% —% (10)% to (5)% Tota
Slide 14: Reconciliation of Historical Non-GAAP Measures
Reconciliation of Historical Non-GAAP Measures % of FY 2023 Revenue % of FY 2022 Revenue % of FY 2021 Revenue % of FY 2020 Revenue % of Q3'2024 Revenue % of Q3'2023 Revenue Total Revenue GAAP Growth Rate 30.0% 18.8% 21.5% 22.5% 25.7% 27.0% Less: Currency Impact 0.4% (3.7)% 1.8% 0.6% 0.3% 1.9% Consta